Articles tagged with Target Proteins
A new way to target the RAS protein, responsible for 20-30% of all known cancers, has been found by a team from the University of Leeds. This breakthrough could lead to greater treatments for more patients, paving the way for hundreds of other disease targets.
Researchers have found that targeting the FK506-binding protein 51 (FKBP51) promotes autophagy and reduces toxic Huntingtin protein levels, potentially providing a new treatment option for Huntington's disease. This new mechanism avoids worrisome side effects associated with rapamycin.
Scientists have identified a promising vaccine target for animal African trypanosomiasis (AAT), a disease causing significant economic impact on livestock in Africa and South America. The vaccine candidate showed long-lasting protection against infection in mice, offering a potential solution to the devastating effects of AAT.
A fixed-dose combination of nivolumab and relatlimab demonstrated a statistically significant benefit over anti-PD-1 monotherapy in metastatic melanoma. The study found that patients treated with the combination therapy had a median progression-free survival of 10.1 months, compared to 4.6 months for those treated with nivolumab alone.
A new combination treatment targeting two proteins may improve survival for T-ALL patients who don't respond to standard chemotherapy. By inhibiting Kinase C and Notch1, researchers aim to overcome drug resistance and enhance treatment efficacy.
A new protein, AIF3, is produced in the brain after a stroke and triggers cell death, providing a potential therapeutic target for preventing or delaying neurodegenerative diseases. Defective splicing of AIF leads to its production, causing mitochondrial dysfunction and cell death.
Researchers at NUS have identified two new proteins that contribute to EV-A71's ability to invade the central nervous system, making them potential targets for treating severe HFMD cases. This discovery could lead to the development of more effective treatments, particularly for young children affected by this illness.
Researchers at the University of Texas MD Anderson Cancer Center have identified a new surface protein, MT1-MMP, as a promising therapeutic target for osteosarcoma. The protein is highly expressed on the surface of osteosarcoma cells but not in normal human tissues, making it an attractive target for antibody-drug conjugate therapy.
A study by LSU Health New Orleans identified how Zika virus disrupts neuronal development, leading to microcephaly and blindness. The research team found that a molecular motor called Kinesin-5 is targeted by the Zika protease, which causes cell division disruptions and loss of function.
The April edition of SLAS Discovery features research on PROTACs, targeting protein degradation, and kinase family profiling. Authors apply the Four Pillars Framework to expedite PROTAC development and inform pharmacokinetic-pharmacodynamic understanding.
A team of University of Alberta researchers has identified a protein that blocks the body's ability to clear low-density lipoprotein (LDL) cholesterol from the blood. This discovery paves the way for developing a new drug to boost existing statin drugs and prevent heart disease.
Researchers at the University of Wisconsin-Madison have developed a new technique to target and destroy disease-causing proteins, which could lead to new drug treatments. By utilizing the cell's own recycling machinery, they aim to restore a healthy balance in cells.
Researchers at Harvard University have designed a new highly-selective tool to study proteins that are difficult to target with drugs, known as 'undruggable' proteins. The tool uses a nanobody to add or remove specific sugars from proteins, providing a detailed understanding of their function.
Researchers have identified a new molecular target, MDM4, that could potentially treat idiopathic pulmonary fibrosis (IPF) by initiating a genetic program to remove scar tissue from the lungs. Targeting this protein may prevent respiratory failure and improve treatment options for patients with IPF.
Researchers are exploring a novel approach to target disease-causing proteins in human cells. This method, utilizing ubiquitin ligases, aims to overcome traditional drug discovery limitations by targeting more disease-causing proteins, offering new therapeutic possibilities for various conditions.
A team of researchers from Harvard University has successfully evolved custom proteases that can target specific proteins with high selectivity, opening up new possibilities for neuroregeneration, growth hormone regulation, and cytokine storm treatment. The technology uses phage-assisted continuous evolution to generate bespoke protein...
A novel gel electrophoresis technique enables rapid biomarker diagnosis via mass spectrometry, overcoming issues with traditional digestion protocols. The method uses dissolvable polyacrylamide gels to recover target proteins, allowing for high-throughput sample preparation and efficient quantification of biomarkers.
Researchers at UT Health San Antonio have identified a human protein called SAMHD1 that can recognize and respond to the HIV virus. This recognition mechanism may lead to a new approach for treating HIV/AIDS by targeting the protein with a specific drug.
Researchers at Tokyo University of Agriculture and Technology developed a new method using easily assembled gold nanoparticles to rapidly understand molecular mechanisms. This approach streamlines the laborious process of identifying target proteins for bioactive small molecules, which can be used in pharmaceutical treatments.
A University of Houston researcher has identified the suPAR protein as a potential therapeutic target for treating focal segmental glomerulosclerosis (FSGS), a common form of kidney disease. High circulating levels of suPAR have been shown to induce oxidative stress in the kidneys, leading to cell damage and kidney failure.
Researchers at DiosCURE developed lead candidates DIOS-202 and DIOS-203 with high potency and resistance to escape mutants. These multivalent single-chain antibodies target two distinct epitopes of the SARS-CoV-2 spike protein, rendering virions non-infectious.
Researchers at CytoDel developed a precision biotherapeutic that can enter neurons and protect SNARE proteins by inhibiting botulinum neurotoxin's catalytic activity. This non-viral delivery method has potential for treating multiple neurological diseases, including synaptopathies.
Researchers developed a novel method to discover ligands and inhibitors against membrane proteins, which are challenging to target. The method uses DNA-programmed affinity labelling and boosting sequences to improve screening specificity and abundance.
A new RNA drug-discovery tool called Chem-CLIP-Fragment Mapping has been developed to address the challenge of 'undruggable' proteins. The tool uses functionalized fragments that can bind to RNAs and modify their structure, enabling the design of medicines against previously untreatable diseases.
Scientists create peptide-oligourea hybrids that mimic natural peptide structures, enhancing drug efficiency and stability. The hybrids exhibit high binding affinities and resist proteolytic degradation.
Researchers have developed new computational tools to speed up molecular dynamics simulations, enabling novel studies on protein behavior. The tools are being used to predict the 3D shape of unknown proteins in COVID-19 viruses, which could lead to new drug developments.
Researchers from Heidelberg University Biochemistry Center have determined the 3D structure of a molecular machine responsible for correctly placing tail-anchored membrane proteins into biomembranes. This finding provides crucial insights into protein transport and insertion, shedding light on the final steps of the process.
Researchers have discovered how the algal pyrenoid, a critical component in carbon fixation, is assembled. A sequence of amino acids, or motif, guides the proteins to the pyrenoid, allowing it to form and function correctly. This discovery sheds light on a long-standing mystery in scientific research.
Researchers have developed a new technology that precisely and rapidly degrades targeted proteins in various organisms. The AID2 system overcomes previous drawbacks of slow degradation rates and requires lower doses of auxin.
A new study suggests that combining T cell activation with antibody production could lead to longer-term protection against Zika virus. Researchers found that inducing CD8+ T cells was key in preventing Zika infection in mice, offering a promising approach for developing effective vaccines.
A team of researchers has identified a mechanism to target amyloid-beta, a disordered protein involved in Alzheimer's disease. By designing drugs that bind to the protein in its disordered state, they hope to reduce toxic cluster formation and develop new treatments.
Scientists have discovered a key mechanism behind SINEUPs, which can amplify protein production by messenger RNAs. The research provides new insights into how these functional non-coding RNAs work and their potential to treat diseases caused by insufficient protein synthesis.
Researchers have successfully multiplied T-cells from COVID-19 recovered patients in the lab, which can effectively target key viral proteins. This approach may be an effective way to protect vulnerable people, especially those with compromised immune systems.
A team of biologists discovered that phytoplasma effector proteins interact with specific molecules in plant hosts, causing developmental abnormalities and devastating changes. The research found that the effector proteins adopt a structure similar to their target host molecules, allowing them to bind and cause harm.
Nagoya University scientists have developed a laboratory technique to rapidly select synthetic proteins that strongly bind to SARS-CoV-2. The approach, called TRAP display, could be used to develop sensitive antigen tests and neutralization antibodies for infected patients.
A new algorithm called Ohm predicts allosteric sites in proteins using their structure, which can aid in protein engineering and drug design. The tool may help reduce unintended side effects caused by drugs targeting similar proteins.
Researchers at Baylor College of Medicine developed an improved type of PROTAC that enhances intracellular accumulation and functions, not only as a degrader but also as an inhibitor of the target protein. The study's findings suggest the possibility of applying this strategy to improve PROTACs for clinical applications.
Scientists have found that a small proportion of individuals possess high levels of antibodies targeting the normal PrP version of the prion protein. These antibodies may be beneficial in targeting pathological aggregates for degradation by phagocytic cells, potentially offering new tools for studying neurodegeneration. The discovery s...
Scientists have observed interaction between therapeutic antibodies and target protein for first time, describing molecular mechanisms. This discovery opens way to development of new synthetic antibodies controlling patient's immune response.
Researchers at Princeton University developed OptoBinders, light-switchable molecular tools that control cellular processes. These antibody-like proteins can bind or release targets in response to blue light, offering new capabilities for protein purification, biofuel production, and targeted cancer therapies.
Researchers at CeMM developed a scalable strategy to discover novel molecular glue degraders, which can eliminate disease-causing proteins by targeting the cellular protein quality control system. The study identifies a set of novel compounds that induce the degradation of cyclin K, essential in many cancer types.
Researchers at the University of Cincinnati have found a potential new combination therapy for breast cancer that integrates use of the body's immune system with targeted treatment for a particular protein called FIP200. This study provides data that could eventually lead to a new breast cancer therapy.
A research team has discovered a new mechanism for balancing protein stability during neuronal development, using heat shock proteins to regulate microtubule stability and axonal growth. This discovery can help understand neurodevelopmental diseases, nerve regeneration, and neurodegenerative diseases.
A monoclonal antibody targeting mutant huntingtin protein effectively binds and depletes the protein from cell culture supernatants, blocking its secretion and uptake. This suggests that mAB C6-17 could interfere with pathological processes of mutant huntingtin spreading in vivo.
Scientists have developed a new approach to chromatin immunoprecipitation (ChIP) called FloChIP, which uses microfluidics to automate and lower the cost and complexity of the technique. This method can perform multiple ChIP-seq assays simultaneously and reproducibly in an automated way.
Researchers discovered that the Mediator complex selectively safeguards a small set of cell-type-specific genes, which form densely connected regulatory circuits. This finding suggests that Mediator is not generally required for all gene transcription and instead plays a crucial role in directing cell-type-specific functions.
A special collection in SLAS Discovery highlights new screening tools and assays for ion channel drug discovery. The articles cover various techniques such as optical and automated patch clamp electrophysiology to identify new chemical matter for medically relevant membrane protein targets.
Researchers at CNIC have created a novel mouse model that enables the direct analysis of protein mechanical function. The model, based on titin and HaloTag-TEV genetic cassette, allows for controlled disruption of protein mechanics to study cellular responses.
A team of researchers from the University of Toronto has delayed the onset of amyotrophic lateral sclerosis (ALS) in mice by preventing neuron degeneration. The result, combined with other clinical advances, holds promise for a potential treatment for ALS in humans.
Researchers at Skoltech and MIT have developed a new combinatorial therapy for liver cancer using a siRNA approach coupled with lipid nanoparticle technology. This treatment caused a significant decrease in tumor load in a mouse model of hepatocellular carcinoma.
Researchers at the University of Wisconsin-Madison have identified vimentin as a crucial component in the protein-management system of neural stem cells. The study found that vimentin brings proteasomes to clumps of damaged proteins, allowing for their efficient clearance and enabling neural stem cells to function properly.
Researchers at Osaka University have reported a straightforward approach to protein modification by targeting the N-terminus, providing a new tool for protein engineering. The method uses a single-step reaction to conjugate functional molecules to proteins, resulting in highly efficient site-specific labeling under mild conditions.
Researchers discovered autophagy's selective degradation of protein liquid droplets but poor performance with aggregated proteins. This study used yeast and a test tube system to reconstitute the Ape1 isolation process, revealing the role of Atg8 and receptor proteins.
A new biomarker for detecting liver metastases has been identified by a Georgia State University research team. The breakthrough uses a targeted MRI contrast agent that can pinpoint tiny instances of cancer cells, overcoming major barriers in early diagnosis.
A collaboration between Rutgers University and Scripps Research has led to the discovery of a small molecule that reduces α-synuclein protein levels, potentially slowing or stopping Parkinson's disease progression. This finding offers hope for early-stage patients and may be applicable to other neurodegenerative diseases like Alzheimer's.
Researchers at Ben-Gurion University and The Hebrew University of Jerusalem developed a powerful tool that streamlines the development of disease therapies, transforming a multi-year process into just a few days. The new approach simultaneously evaluates thousands of mutations in protein-protein complexes, increasing understanding of m...
Researchers at Ludwig-Maximilians-Universität München have developed a tool that allows for the selective degradation of essential proteins in cells using light or chemicals. This method enables the study of protein function without relying on genetic mutations or gene deletion, which is often not possible for essential proteins.
Researchers at Kobe University developed a method to control protein anchorage position in engineered yeast cells, improving ethanol production by 30% and increasing potential applications in bio-production and medicine. This technique utilizes anchoring domains to manipulate protein location on the cell surface.
Integral Molecular has developed a panel of fully humanized P2X7 antibodies against autoimmune disorders like atopic dermatitis and glomerulonephritis. The company's MPS Antibody Discovery platform successfully isolated high-affinity antibodies with antagonist or rare agonist activity.
A study published in Nature Medicine reveals a potential 'liquid health check' that uses proteins in blood to predict disease risk and improve preventative medicine. The technique, involving large-scale measurement of proteins, has shown promise for identifying health states and conditions, such as diabetes and cardiovascular disease.